Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.
Daniel M GirardiScot A NiglioAmir MortazaviRosa NadalPrimo LaraSumanta K PalBiren SaraiyaLisa CordesLisa LeyOlena Sierra OrtizJacqueline CadenaCarlos DiazHadi BagheriBernadette ReddSeth M SteinbergRene CostelloKeith S ChanMin-Jung LeeMin-Jung LeeYunkai YuSandeep GurramHeather J ChalfinVladimir ValeraWilliam Douglas FiggMaria J MerinoAntoun ToubajiHoward StreicherJohn J WrightElad SharonHoward L ParnesYang-Min NingDonald P BottaroLiang CaoJane B TrepelAndrea B ApoloPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
CaboNivo was clinically active, well tolerated, and favorably modulated peripheral blood immune subsets in patients with mUC refractory to CPI.